Radiopharmaceuticals for Bone Metastases-Reference-Cited by-同舟云学术

Radiopharmaceuticals for Bone Metastases

Published:2018 Issue: Volume: Page:345-364
ISSN:
Container-title:Clinical Applications of Nuclear Medicine Targeted Therapy
language:
Short-container-title:

Author:

Pagano Benedetta,Baldari Sergio

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-319-63067-0_26

Reference98 articles.

1. Liepe K, Shinto A. From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases. Ther Adv Med Oncol. 2016;8(4):294–304.

2. Maffioli L, Florimonte L, Costa DC, et al. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer. Q J Nucl Med Mol Imaging. 2015;59:420–38.

3. Guerra Liberal FDC, Tavares AAS, Tavares JMRS. Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153. Appl Rad Isotope. 2016;110:87–99.

4. Bienz M, Saad F. Management of bone metastases in prostate cancer: a review. Curr Opin Support Palliat Care. 2015;9:261–7.

5. Blacksburg SR, Witten MR, Haas JA. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases. Curr Treat Options in Oncol. 2015;16:11.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and characterization of new tetrakisphosphonic acid derivatives as FPPS inhibitors and evaluation of their anti-osteoclastogenic potential for prevention of osteoporosis;Medicinal Chemistry Research;2024-06-05

2. Effect of the [2-(diphenylphosphorylmethoxy)phenyl]diphenylphosphine oxide derivative structures on the extraction and ion-selective properties toward rare-earth elements;Russian Chemical Bulletin;2020-07